APREA THERAPEUTICS INC(NASDAQ:APRE) stock News

APRE Latest News, Press Relases and Analysis

All

Press Releases

5 days ago - By: Benzinga - Mentions: CYH ABP CASI VKTX ...

12 Health Care Stocks Moving In Wednesday's After-Market Session

a month ago - By: Aprea Therapeutics

Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center

a month ago - By: Aprea Therapeutics

Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center

3 months ago - By: Aprea Therapeutics

Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update

a year ago - By: BusinessInsider

APRE Stock Earnings: Aprea Therapeutics Beats EPS, Beats Revenue for Q2 2024

3 months ago - By: Aprea Therapeutics

Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update

4 months ago - By: Aprea Therapeutics

Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial

4 months ago - By: Aprea Therapeutics

Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial

4 months ago - By: Benzinga - Mentions: CORT SNWV INNV PAVM ...

12 Health Care Stocks Moving In Monday's Pre-Market Session

4 months ago - By: Aprea Therapeutics

Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

4 months ago - By: Aprea Therapeutics

Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

5 months ago - By: Aprea Therapeutics

Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)

5 months ago - By: Aprea Therapeutics

Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)

6 months ago - By: Aprea Therapeutics

Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics

6 months ago - By: Aprea Therapeutics

Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics

8 months ago - By: Aprea Therapeutics

Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward

8 months ago - By: Aprea Therapeutics

Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward

9 months ago - By: Aprea Therapeutics

Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

9 months ago - By: Aprea Therapeutics

Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

9 months ago - By: Aprea Therapeutics

Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

9 months ago - By: Aprea Therapeutics

Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

10 months ago - By: Aprea Therapeutics

Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit

10 months ago - By: Aprea Therapeutics

Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit

10 months ago - By: Aprea Therapeutics

Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

10 months ago - By: Aprea Therapeutics

Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

10 months ago - By: Aprea Therapeutics

Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development

10 months ago - By: Aprea Therapeutics

Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development

10 months ago - By: Aprea Therapeutics

Aprea Therapeutics to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024

10 months ago - By: Virtual Investor Conferences - Mentions: NYSE ACST AEMD UNCY ...

Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing

11 months ago - By: Virtual Investor Conferences - Mentions: VNRX CHRO PLX ACST ...